Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab

Despite the successful use of the humanized monoclonal antibody trastuzumab (Herceptin) in the clinical treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, the frequently occurring drug resistance remains to be overcome. The regulatory mechanisms of trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Guoxu, Guo, Zhangyan, Li, Weimiao, Xi, Wenjin, Zuo, Baile, Zhang, Rui, Wen, Weihong, Yang, An-Gang, Jia, Lintao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219715/
https://www.ncbi.nlm.nih.gov/pubmed/34158475
http://dx.doi.org/10.1038/s41392-021-00629-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219715/
https://www.ncbi.nlm.nih.gov/pubmed/34158475
http://dx.doi.org/10.1038/s41392-021-00629-w

Ejemplares similares